Brimonidine Tartrate

本周，NMPA批准的新批文和一致性评价获批受理号共88个，其中，有14个受理号，12个品种，在十批国采。 两个个超级卷的产品，多一家，对最终格局影响很小了。 比如己酮可可碱注射液，已经25个企业； 间苯三酚注射液35个； 而氨茶碱、氯化钾颗粒等，也都是10家以上，多一个名额就多一个竞争，多一份压力。 本次集采的批文截至日期是12月2号，预计下周一可能还有一批，最终决定产品组竞争格局。 点击药品名称，可以查看查询的一致性评价进展。 地高辛注射液氯化钾注射液 乳酸钠林格注射液氨茶碱注射液 己酮可可碱注射液间苯三酚注射液枸橼酸托法替布缓释片硫酸阿米卡星注射液氯化钾颗粒乳酸环丙沙星氯化钠注射液碳酸氢钠林格注射液 以下表格中，加粗显示产品，在十批国采目录。药品名称申请人批准文号受理号氨茶碱注射液裕松源药业有限公司国药准字H20247292CYHB2450204胞磷胆碱钠注射液锦州奥鸿药业有限责任公司国药准字H20247293CYHB2350691胞磷胆碱钠注射液锦州奥鸿药业有限责任公司CYHB2350692胞磷胆碱钠注射液天方药业有限公司CYHB2350757胞磷胆碱钠注射液天方药业有限公司CYHB2350758胞磷胆碱钠注射液天方药业有限公司CYHB2350759胞磷胆碱钠注射液新乡市常乐制药有限责任公司国药准字H20247295CYHB2450107胞磷胆碱钠注射液新乡市常乐制药有限责任公司CYHB2450108贝莫苏拜单抗注射液正大天晴药业集团南京顺欣制药有限公司国药准字S20240017CXSS2400021倍他米松磷酸钠注射液津药和平（天津）制药有限公司国药准字H20249438CYHS2300203本维莫德乳膏上海泽德曼医药科技有限公司国药准字H20240040CXHS2300119单硝酸异山梨酯缓释片南京易亨制药有限公司国药准字H20249430CYHS2302130单硝酸异山梨酯片鲁南制药集团股份有限公司国药准字H20249420CYHS2300869地高辛注射液浙江同伍生物医药有限公司国药准字H20249448CYHS2302199地诺孕素片武汉九珑人福药业有限责任公司国药准字H20249426CYHS2301808地塞米松磷酸钠注射液安徽长江药业有限公司CYHB2350903恩格列净片合肥国高药业有限公司国药准字H20249429CYHS2302112法莫替丁注射液南京丰恺思药物研发有限公司国药准字H20249421CYHS2301153复方聚乙二醇（3350）电解质散重庆迈川医药科技有限公司国药准字H20249440CYHS2300647复方匹可硫酸钠颗粒北京诚济制药股份有限公司国药准字H20249419CYHS2300501富马酸卢帕他定片北京福元医药股份有限公司国药准字H20249437CYHS2302738枸橼酸托法替布缓释片成都康弘药业集团股份有限公司国药准字H20249436CYHS2302608己酮可可碱注射液山东益健药业有限公司CYHB2450158间苯三酚注射液湖北欣泽霏药业有限公司国药准字H20249424CYHS2301724酒石酸伐尼克兰鼻喷雾剂箕星药业科技（上海）有限公司国药准字HJ20240138JXHS2300068酒石酸溴莫尼定滴眼液四川智强医药科技开发有限公司国药准字H20249428CYHS2302090拉坦前列素滴眼液兆科（广州）眼科药物有限公司国药准字H20249433CYHS2302434硫酸阿米卡星注射液浙江康恩贝制药股份有限公司CYHB2350760硫酸沙丁胺醇注射液浙江高跖医药科技股份有限公司国药准字H20249451CYHS2301469氯化钾颗粒海南烨徽源医药科技有限公司国药准字H20247296CYHB2450073氯化钾注射液华润双鹤利民药业（济南）有限公司国药准字H20247294CYHB2350808马来酸氯苯那敏注射液遂成药业股份有限公司CYHB2350506吗啉硝唑氯化钠注射液四川汇宇制药股份有限公司国药准字H20249416CYHS2201499国米诺地尔搽剂杭州康恩贝制药有限公司国药准字H20249417CYHS2300445米诺地尔搽剂杭州康恩贝制药有限公司国药准字H20249454CYHS2300446莫匹罗星软膏江苏知原药业股份有限公司国药准字H20249432CYHS2302180枇杷清肺颗粒仲景宛西制药股份有限公司国药准字C20240008CXZS2400004葡萄糖酸钙注射液洋浦京泰药业有限公司CYHB2350637葡萄糖酸钙注射液国药集团容生制药有限公司CYHB2350980乳果糖口服溶液石药银湖制药有限公司国药准字H20249423CYHS2301489乳酸环丙沙星氯化钠注射液广东大翔制药有限公司国药准字H20247298CYHB2350885乳酸环丙沙星氯化钠注射液广东大翔制药有限公司CYHB2350886乳酸钠林格注射液四川美大康佳乐药业有限公司CYHB2350923赛洛多辛胶囊浙江普利药业有限公司国药准字H20249444CYHS2301298沙美特罗替卡松吸入粉雾剂杭州京瑞医药科技有限公司国药准字HJ20240136JYHS2300023沙美特罗替卡松吸入粉雾剂杭州京瑞医药科技有限公司国药准字HJ20240137JYHS2300024芍药甘草颗粒合肥华润神鹿药业有限公司国药准字C20240007CXZS2300013索米妥昔单抗注射液杭州中美华东制药有限公司国药准字SJ20240044JXSS2300079碳酸氢钠林格注射液安徽双鹤药业有限责任公司国药准字H20249422CYHS2301414碳酸氢钠注射液昆明南疆制药有限公司国药准字H20247291CYHB2350836替普瑞酮胶囊四川国为制药有限公司国药准字H20249439CYHS2300377头孢丙烯片悦康药业集团股份有限公司CYHB2450055西洛他唑片宏越科技（湖州）有限公司国药准字H20249441CYHS2300755西咪替丁注射液温岭市创新生物医药科技股份有限公司国药准字H20249450CYHS2300880硝酸异山梨酯注射液上海上药第一生化药业有限公司CYHB2350881硝酸异山梨酯注射液辰欣药业股份有限公司国药准字H20249434CYHS2302455亚叶酸钙注射液成都瑞尔医药科技有限公司国药准字H20249435CYHS2302508盐酸安罗替尼胶囊正大天晴药业集团股份有限公司国药准字H20180002CXHS2400016盐酸安罗替尼胶囊正大天晴药业集团股份有限公司国药准字H20180004CXHS2400017盐酸安罗替尼胶囊正大天晴药业集团股份有限公司国药准字H20180003CXHS2400018盐酸氨溴索口崩片重庆康刻尔制药股份有限公司CYHB2350728盐酸胺碘酮注射液浙江普利药业有限公司国药准字H20249442CYHS2300796盐酸胺碘酮注射液浙江普利药业有限公司国药准字H20249443CYHS2300797盐酸丙卡特罗吸入溶液深圳大佛药业股份有限公司国药准字H20249447CYHS2302067盐酸伐地那非片国药控股星鲨制药（厦门）有限公司国药准字H20249431CYHS2302147盐酸莫西沙星氯化钠注射液哈尔滨珍宝制药有限公司国药准字H20249449CYHS2300145盐酸哌罗匹隆片四川科瑞德制药股份有限公司国药准字H20249452CYHS2301593盐酸替罗非班氯化钠注射液河南润弘制药股份有限公司国药准字H20249445CYHS2301306盐酸替罗非班氯化钠注射液河南润弘制药股份有限公司国药准字H20249446CYHS2301307盐酸托莫西汀胶囊天方药业有限公司国药准字H20247297CYHB2450076盐酸托莫西汀胶囊天方药业有限公司CYHB2450077一贯煎颗粒吉林敖东洮南药业股份有限公司国药准字C20240009CXZS2400005乙酰半胱氨酸颗粒南京易亨制药有限公司国药准字H20249427CYHS2301958异烟肼注射液石药银湖制药有限公司CYHB2350868注射用A型肉毒毒素上海复星医药产业发展有限公司国药准字SJ20240041JXSS2300053注射用氨磷汀四川汇宇海玥医药科技有限公司国药准字H20249418CYHS2300477注射用苯唑西林钠湖南科伦制药有限公司CYHB2450067注射用苯唑西林钠湖南科伦制药有限公司CYHB2450068注射用更昔洛韦湖北长联杜勒制药有限公司CYHB2350784注射用利纳西普杭州中美华东制药有限公司国药准字SJ20240045JXSS2300084注射用芦康沙妥珠单抗四川科伦博泰生物医药股份有限公司国药准字S20240052CXSS2300093注射用泮托拉唑钠浙江亚太药业股份有限公司CYHB2350599注射用泮托拉唑钠浙江亚太药业股份有限公司CYHB2350600注射用泮托拉唑钠浙江亚太药业股份有限公司CYHB2350601注射用维库溴铵中玉制药（海口）有限公司CYHB2350503注射用亚胺培南西司他丁钠国药集团国瑞药业有限公司CYHB2350752左氧氟沙星片白云山汤阴东泰药业有限责任公司国药准字H20249453CYHS2301797左氧氟沙星片白云山汤阴东泰药业有限责任公司国药准字H20249425CYHS2301798 使用”摩熵药筛“小程序，可以查询国采产品的竞争、价格、市场销售数据。 十批国采分享微信群已建，欢迎企业和代理商入群，对接资源。 加客服小狐微信，拉你入群！

The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by Viatris and Ocuphire Pharma, BRIMOCHOL PF (VT-1011) by Visus Therapeutics, among others will significantly impact the presbyopia market during the forecast period (2024–2034). LAS VEGAS, Nov. 14, 2024 /PRNewswire/ -- Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages 40 and 60. It results from the lens losing elasticity and becoming thicker, harder, and less flexible due to structural protein changes. This impairs the lens's ability to adjust for near vision, reducing accommodative amplitude. Presbyopia can be classified into incipient, functional, absolute, premature, and nocturnal types, each representing different stages and manifestations of the condition. As per DelveInsight's assessment, the total prevalent cases of presbyopia in the 7MM were ~325 million in 2023. These cases are expected to increase at a significant CAGR of 1.1% during the forecast period i.e., 2024–2034. Based on severity, presbyopia was bifurcated into mild and moderate to severe presbyopia, in EU4 and the UK, moderate to severe presbyopia accounted for the maximum number of cases, which was approximately 95 million. Treatment options for presbyopia mainly consist of corrective lenses and surgical procedures. Non-invasive methods, such as reading glasses, bifocals, and progressive lenses, enhance vision at different distances. Contact lenses, including multifocal and monovision types, present another option. Surgical treatments like LASIK, conductive keratoplasty, and corneal inlays modify the eye's focusing capabilities. Recently, eye drops like pilocarpine hydrochloride have gained attention as a promising treatment, as they temporarily enhance near vision by constricting the pupil to improve depth of field. For non-drug treatments, reading glasses enable clear vision for tasks up close, while bifocals combine two prescriptions in a single lens to correct both distance and near vision. Progressive lenses provide a smooth transition between different vision zones with no visible lines. Contact lenses designed for presbyopia, like multifocal or accommodating lenses, offer greater convenience and a broader field of vision compared to glasses. For those looking for a more lasting solution, LASIK surgery can correct presbyopia by reshaping the cornea, although it tends to be more effective for younger individuals with stable vision needs. Conductive keratoplasty uses radiofrequency energy to enhance near vision by creating small spots on the cornea, serving as a non-invasive option. Corneal inlays involve inserting a tiny device into the cornea to enhance near vision while maintaining distance vision. Two FDA-approved treatments, VUITY and QLOSI, represent significant advancements in ophthalmology. Learn more about the FDA-approved presbyopia drugs @ Drugs for Presbyopia Treatment VUITY (1.25% pilocarpine HCl ophthalmic solution), developed by Allergan, is a groundbreaking treatment for presbyopia that received FDA approval in October 2021. This prescription eye drop functions by constricting the pupil, which improves near and intermediate vision while minimally impacting distance vision. Utilizing the miotic effects of pilocarpine, VUITY enhances focus for close-range activities, presenting a non-invasive alternative to reading glasses. Its approval represents a significant step forward in managing presbyopia, offering patients a convenient and effective solution to relieve the symptoms associated with the condition. QLOSI (0.4% pilocarpine hydrochloride ophthalmic solution), developed by Orasis Pharmaceuticals, is a new treatment for presbyopia that received approval from the US FDA in October 2023. This formulation utilizes pilocarpine, a cholinergic muscarinic agonist, to enhance the eye's ability to focus on nearby objects. The launch of QLOSI is expected in the latter half of 2024, providing patients with a non-surgical option for addressing age-related vision deterioration. To know more about presbyopia treatment options, visit @ New Treatment for Presbyopia The dynamics of the presbyopia treatment market are anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment-based unmet needs. Key players, such as Viatris and Ocuphire Pharma (Phentolamine Ophthalmic Solution 0.75%), Visus Therapeutics (BRIMOCHOL PF), Lenz Therapeutics (LNZ100), and others are involved actively in developing potential treatment scopes. Discover which therapies are expected to grab major presbyopia market share @ Presbyopia Market Report LNZ100, developed by Lenz Therapeutics, is an experimental treatment for presbyopia that is currently progressing through Phase III clinical trials. This medication works by targeting and modulating the intraocular muscles to restore the eye's ability to focus on nearby objects, which is a common problem associated with aging. LNZ100 utilizes a unique mechanism of action that selectively modulates specific receptors in the eye to improve accommodation. Administered as eye drops, LNZ100 provides a non-invasive alternative to surgical treatments. The company intends to submit a New Drug Application (NDA) to the FDA in mid-2024, with plans for a market launch in the second half of 2025, establishing it as a significant therapeutic option for presbyopia management. BRIMOCHOL PF (VT-1011) is a drug under development by Visus Therapeutics aimed at treating presbyopia. This combination therapy includes carbachol and brimonidine tartrate and is designed to enhance near vision by utilizing its pharmacodynamic properties. Currently, BRIMOCHOL PF is in Phase III of clinical development. Following promising results from Phase II trials, it has advanced to this crucial stage, where the primary focus is to validate its therapeutic effects and detect any possible side effects before pursuing regulatory approval for market launch. The company plans to submit its New Drug Application (NDA) in the latter half of 2024, intending to provide a new treatment option for presbyopia. Phentolamine Ophthalmic Solution 0.75%, being developed by Viatris and Ocuphire Pharma, aims to treat presbyopia. This solution enhances near vision temporarily while maintaining distance vision, providing a non-surgical option to reading glasses or contact lenses. The development of Phentolamine Ophthalmic Solution 0.75% is in the final phases of clinical trials. It has successfully finished Phase II studies, which showed its efficacy and safety for the intended purpose. The product is currently in Phase III clinical trials to further verify its effectiveness and safety before pursuing regulatory approval. Discover more about drugs for presbyopia in development @ Presbyopia Clinical Trials The anticipated launch of these emerging therapies for presbyopia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the presbyopia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for presbyopia is expected to grow from USD ~17 billion in 2023 with a CAGR of 3.2% by 2034. The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising incidence of the condition, which together foster a higher demand for innovative and effective therapies. DelveInsight's latest published market report titled as Presbyopia Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the presbyopia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The presbyopia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Presbyopia Total Diagnosed Prevalent Cases of Presbyopia Gender-specific Diagnosed Prevalent Cases of Presbyopia Age-specific Diagnosed Prevalent Cases of Presbyopia Severity-specific Diagnosed Prevalent Cases of Presbyopia The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM presbyopia market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this presbyopia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the presbyopia market. Also, stay abreast of the mitigating factors to improve your market position in the presbyopia therapeutic space. Related Reports Presbyopia Pipeline Presbyopia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, among others. Myopia Market Myopia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Pipeline Myopia Pipeline Insight – 2024 report provides comprehensive insights into pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myopia companies involved, such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Progression Market Myopia Progression Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia progression companies such as Johnson & Johnson Vision Care Inc, Beijing Airdoc Technology Co., Ltd, Essilor International, Menicon Co., Ltd., SightGlass Vision Inc, Indizen Optical Technologies, S.L.U., Bausch & Lomb Incorporated, Coopervision Inc, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED